Literature DB >> 16873289

Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?

Paul N Span1, Vivianne C G Tjan-Heijnen, Joop J T M Heuvel, Jacques B de Kok, John A Foekens, Fred C G J Sweep.   

Abstract

BACKGROUND: A total of 4 additional splice variants (survivin-DeltaEx3, survivin 2alpha, survivin-2B, and survivin-3B) have been described for survivin [baculoviral IAP repeat-containing protein (BIRC-5), approved gene symbol BIRC5], which has been implicated in both inhibition of apoptosis and regulation in mitosis in many tumor types. In this study, we assessed whether the survivin splice variants modulate or add to the prognostic value of total survivin in breast cancer.
METHODS: With quantitative reverse transcription-PCR, we measured mRNA concentrations of survivin and all variants in tumor tissue from 275 patients with breast cancer and associated these with clinicopathologic characteristics and relapse-free survival.
RESULTS: Total survivin, survivin-DeltaEx3, and survivin 2alpha mRNA levels were associated with young age and ductal histology. Total survivin and survivin-DeltaEx3 were highest in samples with advanced histological grade, whereas patients with 4-9 involved lymph nodes expressed less survivin-2B mRNA than those with 1-3 involved nodes. All variants were higher in tumors negative for steroid hormone receptors. Total survivin, survivin 2alpha, and survivin-3B were associated with poor relapse-free survival in univariate analyses. Survivin 2alpha and survivin-3B added to the prognostic value of total survivin in multivariate analyses. In addition, the prognostic value of total survivin was evident only in the presence of higher expression levels of these 2 variants.
CONCLUSIONS: All variants of survivin exhibited particular associations with clinicopathologic characteristics (age, histology, grade, and steroid hormone receptor status) of breast cancer patients. Survival analyses suggest a modulating role of survivin 2alpha and survivin-3B on the biological function of total survivin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873289     DOI: 10.1373/clinchem.2006.071613

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

1.  Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma.

Authors:  Chao-Ping Ye; Cheng-Zhi Qiu; Zhong-Xin Huang; Qi-Chen Su; Wei Zhuang; Rui-Lan Wu; Xin-Feng Li
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 2.  Prognostic value of survivin expression in breast cancer patients: a meta-analysis.

Authors:  Jian Song; Hong Su; Yang-Yang Zhou; Liang-Liang Guo
Journal:  Tumour Biol       Date:  2013-05-21

3.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

Review 4.  Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Authors:  Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

5.  Survinin expression in patients with breast cancer during chemotherapy.

Authors:  S R Marsicano; R K Kuniyoshi; F S Gehrke; B C A Alves; L A Azzalis; F L A Fonseca
Journal:  Tumour Biol       Date:  2014-12-24

6.  The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival.

Authors:  Anna G Antonacopoulou; Konstantina Floratou; Vasiliki Bravou; Anastasia Kottorou; Fotinos-Ioannis Dimitrakopoulos; Stella Marousi; Michalis Stavropoulos; Angelos K Koutras; Chrisoula D Scopa; Haralabos P Kalofonos
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

Review 7.  Association of survivin splice variants with prognosis and treatment of breast cancer.

Authors:  Anastasia Pavlidou; Christos Kroupis; Kleanthi Dimas
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Authors:  Quan-Xing Ge; Yu-Yuan Li; Yu-Qiang Nie; Wen-Ge Zuo; Yan-Lei Du
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

9.  Expression of survivin and its splice variants in gastric cancer.

Authors:  Zhengjiang Cheng; Lihua Hu; Wenrong Fu; Qin Zhang; Xiaofeng Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

Review 10.  Survivin splice variants and their diagnostic significance.

Authors:  Nand K Sah; Chandrabhan Seniya
Journal:  Tumour Biol       Date:  2015-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.